Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Aisha Shaikh

General Nephrology · UPenn

View

Dr. Anna Gaddy

General Nephrology · MCW

View

Dr. Laura Maursetter

General Nephrology · UW

View

Dr. Lavinia Negrea

General Nephrology · CWRU

View

Dr. Chi-yuan Hsu

General Nephrology · UCSF

View

Dr. Adam Weinstein

General Nephrology · DaVita

View

Dr. Daniel Batlle

General Nephrology · Northwestern Medicine

View

Dr. Sushrut Waikar

General Nephrology · BMC

View

Dr. Keith Bellovich

General Nephrology · HFHS

View

Dr. Steven Fishbane

General Nephrology · Northwell Health

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.

    Feb 24, 2026DOI: 10.1161/circulationaha.125.075157Journal ArticleAHA

    Written by: Yang XuTao HuangYue ZhangDongze JiKatherine R TuttleJuan-Jesus CarreroEdouard L Fu

    Find these authors on Roon

    KT
    Dr. Katherine Tuttle
    General Nephrology · Providence Health

    Summary

    BACKGROUND: Novel treatments are needed for the primary and secondary prevention of heart failure in patients with type 2 diabetes, including individuals with and those without a history of heart failure. Conflicting trial evidence exists on whether glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce the risk of hospitalization for heart failure (HHF) in this broad population and whether this is a class effect or varies by specific agent. Furthermore, their comparative effectiveness against sodium-glucose cotransporter-2 inhibitors (SGLT-2is) is unknown.METHODS: We emulated 2 target trials using population-based health care data from Stockholm, Sweden (2010-2021). Target trial 1 included adult patients with type 2 diabetes who newly initiated GLP-1RA versus dipeptidyl peptidase-4 inhibitors (DPP-4is), and target trial 2 compared GLP-1RA with SGLT-2i. The primary outcome was HHF. Cox regression was used to estimate intention-to-treat hazard ratios, with inverse probability of treatment weighting used to balance 72 confounders. Major adverse cardiovascular events were used as the positive control outcome. Analyses were conducted for the GLP-1RA class overall and for individual agents, including liraglutide and semaglutide.RESULTS: Target trial 1 included 32 979 patients (42% GLP-1RA and 58% DPP-4i) with a mean age of 64 years and 40% female; and target trial 2 included 30 104 patients (49% GLP-1RA and 51% SGLT-2i) with a mean age of 63 years and 38% female. Starting a GLP-1RA was associated with a lower 3-year absolute risk of HHF than starting a DPP-4i (3.4% versus 4.3%), corresponding to a weighted hazard ratio of 0.77 (95% CI, 0.66-0.91). Absolute 3-year risks for GLP-1RA compared with SGLT-2i on HHF were 3.6% and 3.3% with a weighted hazard ratio of 1.02 (95% CI, 0.85-1.18). The absolute risk difference was largest for patients with higher predicted risk of heart failure at baseline. Results were consistent for single agents, in per-protocol analyses, and in the majority of subgroups. In positive control outcome analyses, GLP-1RA use was associated with a lower rate of major adverse cardiovascular events than DPP-4i use (weighted hazard ratio, 0.85 [95% CI, 0.74-0.99]), consistent with trial findings.CONCLUSIONS: GLP-1RA use is associated with a lower risk of HHF compared with DPP-4i and similar risks compared with SGLT-2i in routine clinical care for patients with type 2 diabetes.
    KTDr. Katherine Tuttle

    Dr. Katherine Tuttle

    Nephrology · General Nephrology
    Providence Health
    katherinet